Real World Evidence – Accelerated patient access.

How will the drug behave in the complex, unpredictable real world?

More on Real World Evidence

Latest Reads


Real World Evidence


Multidimensional Evidence Generation and FDA Regulatory Decision Making


Real World Evidence


Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician


Real World Evidence


The Expanding Role of Real-World Evidence Trials in Health Care Decision Making


Real World Evidence


Can real-world data really replace randomised clinical trials?


Real World Evidence


Modernizing Regulatory Evidence with Trials and Real-World Studies

We need understand what happens in actual clinical practice and use that to inform treatment and reimbursement decisions.

For decades, randomised clinical trials have been the gold standard for demonstrating a potential new medicine is safe & effective. Nowadays, however, payers, policymakers and suffering patients are demanding more.

As the research and healthcare landscape shifts towards increasing personalisation of treatment, rising emergence of rare diseases and earlier access, it is grappling  simultaneously with high costs and lengthy timelines when delivering medicine to patients. Real world evidence has the potential to help facilitate access and address some of this burden, whilst providing a better understanding of medicines ‘real world’ use.

The impact of real world data:
A representative of everyday clinical practice

Real-World Data (RWD) is data relating to patient health status and the delivery of healthcare collected regularly from a variety of sources. These sources provide reliable evaluations on three pillars of RWE Studies.

RWE analytics delivers valuable information, from the frontline of healthcare systems. This data leads the conversation with payers, healthcare providers, and regulators to make more holistic and informed healthcare decisions.

Improved data collection enables safer studies when scaling study populations, whilst upholding gold standard patient care and integration.

Humanistic data, typically focused on quality of life measures important to patients.
Clinical data, which helps evaluate a drug’s safety and effectiveness.
Economic data, used to evaluate its value.